Nasopharynx in CF Patients May Be Where Bacterial Infections Hide

A new study, entitled, “Pseudomonas aeruginosa adaptation in the nasopharyngeal reservoir leads to migration and persistence in the lungs,” conducted at the University of Liverpool’s Institute of Infection and Global Health, UK, published in Nature Communications, and led by the group of the Professors Aras Kadioglu and Craig Winstanley, show for the first time a new reservoir of infection, the nasopharynx, by Pseudomonas aeruginosa that may explain recurrent infections and the development of chronic lung infection in patients with cystic fibrosis (CF). Continue reading Nasopharynx in CF Patients May Be Where Bacterial Infections Hide

Voting Is Now Open! Help Two Students with Cystic Fibrosis Win $22K toward Higher Ed

The AbbVie CF Scholarship was established 22 years ago to honor young adults with cystic fibrosis (CF) as they pursue goals of higher education. Since then, more than 500 students with CF have received more than $2.4 million in educational funding. Continue reading Voting Is Now Open! Help Two Students with Cystic Fibrosis Win $22K toward Higher Ed

Calling All ‘Foodies!’

Come one, come all, and submit your favorite family recipes by August 8 to help raise $5,000 for CFRI through CFChef Shares, an exciting new partnership between AbbVie and CFRI to promote awareness of proper nutrition for those living with CF. Continue reading Calling All ‘Foodies!’

CUHK Research Explains Why Patients with Cystic Fibrosis Often Develop Diabetes

Recent research led by Professor CHAN Hsiao Chang, Li Ka Shing Professor of Physiology and Director of the Epithelial Cell Biology Research Centre at The Chinese University of Hong Kong (CUHK), explains why patients with cystic fibrosis often develop diabetes. The study also suggests a potential treatment strategy for cystic fibrosis associated diabetes. The finding has been published in an international leading scientific journal, Nature Communications. Continue reading CUHK Research Explains Why Patients with Cystic Fibrosis Often Develop Diabetes

Gunnar Esiason Launches New Blog

Our very own Gunnar Esiason launched a blog to share his story
of living with cystic fibrosis.

“I want to use this blog to share some of my experiences so that hopefully when you, whoever you Continue reading Gunnar Esiason Launches New Blog

Cystic fibrosis services helps meet demand for high-quality patient care

Underscoring its commitment to the cystic fibrosis (CF) community, Walgreens now offers enhanced personalized therapy management support to help people with CF live healthier lives. Connected CareSM Cystic Fibrosis Management Program is provided through Cystic Fibrosis Continue reading Cystic fibrosis services helps meet demand for high-quality patient care

Application Now Open for Students with Cystic Fibrosis for the 2014 AbbVie CF Scholarship

AbbVie today announced that undergraduate and graduate students living with cystic fibrosis (CF) can now apply for the 2014 AbbVie CF Scholarship, which honors young adults with CF as they pursue higher education. Students can apply for the scholarship from now until Monday, June 9, at     www.AbbVieCFScholarship.com .                           Continue reading Application Now Open for Students with Cystic Fibrosis for the 2014 AbbVie CF Scholarship

New Cystic Fibrosis Clinical Trial to be Launched by Kamada Ltd. this Summer

Israel-based Kamada Ltd., a drug development company currently developing plasma-derived protein therapeutics that are chiefly targeting orphan diseases, indicated recently in a press release that their lead drug candidate Alpha-1 Antitrypsin (AAT), which is currently in trials for treatment of Alpha-1 Antitrypsin Deficiency (AATD, or Inherited Emphysema), will also be tested in a new round of clinical trials for cystic fibrosis this summer. Continue reading New Cystic Fibrosis Clinical Trial to be Launched by Kamada Ltd. this Summer

N30 Pharmaceuticals Initiates Phase 1 Clinical Trial for Novel Cystic Fibrosis Therapy

BOULDER, Colo., March 12, 2014 /PRNewswire/ — N30 Pharmaceuticals, Inc. (“N30 Pharma”) announced today that it has begun oral dosing of N91115 in a Phase 1 clinical trial. N91115, a novel inhibitor of S-nitrosoglutathione reductase (GSNOR), is being developed for the treatment of cystic fibrosis (CF). Continue reading N30 Pharmaceuticals Initiates Phase 1 Clinical Trial for Novel Cystic Fibrosis Therapy

New Cystic Fibrosis Sweat Test Offers More Accurate Results

The Cystic Fibrosis Foundation describes CF as a genetically-acquired chronic disease that impacts the lungs and gastrointestinal tract, causing these body systems to produce abnormally thick, and viscid mucus that has the tendency to consolidate in the lungs, and block the secretion of pancreatic enzymes, resulting in malabsorption. Today, about 30,000 American children and adults, and over 70,000 people are affected all over the globe. Stanford researchers have recently come up with a breakthrough sweat test for those living with Cystic Fibrosis that promises to reveal more about the disease. Continue reading New Cystic Fibrosis Sweat Test Offers More Accurate Results